Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Optimer Pharmaceuticals
So what: Optimer just reported fantastic sales in the third quarter but still saw a disappointingly large net loss. Impatient investors appear disillusioned by the prognosis that bacterial-diarrhea treatment Dificid won't break even for about three years.
Now what: The market drop notwithstanding, two analyst firms reupped their respective buy ratings on Optimer today with price targets between $19 and $20 per share. Clostridium difficile-related diarrhea doesn't present a huge market like prostate cancer does for Dendreon
Interested in more info about Optimer Pharmaceuticals? Click here to add it to My Watchlist.